The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for 'Trial within Cohorts' study designs

Yildirim, H.; Widdershoven, C.V.; Aarts, M.J.B.; Bex, A.; Bloemendal, H.J.; Bochove-Overgaauw, D.M.; ... ; Bins, A.D. (2023)

Article / Letter to editor

Background Ongoing research in the field of both localized, locally advanced and metastatic renal cell carcinoma has resulted in the availability of multiple treatment options. Hence, many questions are still unanswered and await further research. A nationwide collaborative registry allows to collect corresponding data. For this purpose, the Dutch PROspective Renal Cell Carcinoma cohort (PRO-RCC) has been founded, for the prospective collection of long-term clinical data, patient reported outcome measures (PROMs) and patient reported experience measures (PREMs).Methods PRO-RCC is designed as a multicenter cohort for all Dutch patients with renal cell carcinoma (RCC). Recruitment will start in the Netherlands in 2023. Importantly, participants may also consent to participation in a 'Trial within cohorts' studies (TwiCs). The TwiCs design provides a method to perform (randomized) interventional studies within the registry. The clinical data collection is embedded in the Netherlands Cancer Registry (NCR). Next to the standardly available data on RCC, additional clinical data will be collected. PROMS entail Health-Related Quality of Life (HRQoL), symptom monitoring with optional ecological momentary assessment (EMA) of pain and fatigue, and optional return to work- and/or nutrition questionnaires. PREMS entail satisfaction with care. Both PROMS and PREMS are collected through the PROFILES registry and are accessible for the patient and the treating physician.Discussion PRO-RCC is a nationwide long-term cohort for the collection of real-world clinical data, PROMS and PREMS. By facilitating an infrastructure for the collection of prospective data on RCC, PRO-RCC will contribute to observational research in a real-world study population and prove effectiveness in daily clinical practice. The infrastructure of this cohort also enables that interventional studies can be conducted with the TwiCs design, without the disadvantages of classic RCTs such as slow patient accrual and risk of dropping out after randomization.

• Kidney cancer
• Renal cell carcinoma
• Urological cancer

• All authors: Yildirim, H.; Widdershoven, C.V.; Aarts, M.J.B.; Bex, A.; Bloemendal, H.J.; Bochove-Overgaauw, D.M.; Hamberg, P.; Herbschleb, K.H.; Hulle, T. van der; Lagerveld, B.W.; Oijen, M.G.H. van; Oosting, S.F.; Thienen, J.V. van; Veldt, A.A.M. van der; Westgeest, H.M.; Zeijdner, E.E.; Aben, K.K.H.; Hurk, C. van den; Zondervan, P.J.; Bins, A.D.
• Date: 2023-07-11
• Journal: BMC Cancer
• Volume: 23
• Issue: 1
• DOI: doi:10.1186/s12885-023-11094-9
• Link: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-11094-9